Brief: Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-Osa Trial Results
09/03/2026 21:37
March 9 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NDA FOR LORUNDROSTAT FOR TREATMENT OF ADULTS WITH HYPERTENSION AND TOPLINE EXPLORE-OSA TRIAL RESULTS MINERALYS THERAPEUTICS INC - FDA ASSIGNS PDUFA TARGET ACTION DATE OF DECEMBER 22, 2026 FOR LORUNDROSTAT NDA Source text: ID:nGNX6xHsyL Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway